September 26, 2003 - SAN DIEGO - Women First HealthCare Inc. (Nasdaq: WFHC - News) today announced that it has entered into a comprehensive agreement with Target Software to automate its field sales force using the Target SFA software.

According to Saundra Pelletier, VP-Pharmaceuticals "Our strategic shift towards an expanded sales force and the coverage of both dermatologists and Ob/Gyns will be better controlled through the implementation of Target SFA. This tool will also allow us to further grow our prescriptions for both Esclim and Vaniqa with more timely data. We've been interested in automating our field sales force for quite some time and this will reduce our dependence on outside service providers, help to eliminate inefficient paper processes, and ultimately help us increase the market share for our products with greater management control. The investment in automation further demonstrates our commitment to full PDMA compliance and to the growth of our sales organization. This is the latest step in our ongoing strategy to become a more nimble, cutting-edge sales team."

The Women First HealthCare sales force will be deployed on Target SFA in January 2004.

About Esclim(TM)

Women First markets Esclim(TM) (estradiol transdermal system) exclusively in the U.S. under a distribution and licensing agreement with Laboratoires Fournier SA of France. Its active ingredient is estradiol, the principal form of estrogen produced naturally by a woman's ovaries during the reproductive years. The Esclim(TM) transdermal patch system offers maximum dosing flexibility with five dosage options (0.025, 0.0375, 0.05, 0.075, and 0.1 mg/day) and is applied twice weekly. Esclim(TM) provides a unique ethylene vinyl acetate (EVA) matrix system with flexible foam backing to assure suppleness that follows the movements of a woman's skin.

Esclim(TM) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of vasomotor menopausal symptoms such as hot flashes and night sweats.

The most commonly reported side effects of Esclim(TM) are those typical of estrogen replenishment therapy: breast tenderness, headache, nausea, and abdominal pain. Estrogens have been reported to increase the risk of endometrial carcinoma in postmenopausal women. Estrogens are contraindicated in patients with known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, known or suspected estrogen-dependent neoplasia, or active thrombophlebitis or thromboembolic disorders.

About Women First HealthCare Inc.

Women First HealthCare Inc. (Nasdaq: WFHC - News) is a San Diego-based specialty pharmaceutical company. Founded in 1996, its mission is to help midlife women make informed choices regarding their health care and to provide pharmaceutical products -- the company's primary emphasis -- and lifestyle products to meet their needs. Women First HealthCare is specifically targeted to women age 40+ and their clinicians. Further information about Women First HealthCare can be found online at www.womenfirst.com, About Us and Investor Relations.

About Target Software Inc.

Target Software (www.targetsfa.com), founded in 1991, is a provider of mobile sales force automation and sample accountability solutions for the pharmaceutical industry. The Target SFA suite features Target Mobile, a family of state-of-the-art mobile sales solutions for the Pocket PC, Windows, Web and Tablet PC platforms. Target BackOffice is Target Software's fully PDMA-compliant and validated call reporting and sample accountability solution.

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," and "would." Such forward-looking statements are subject to various risks, and Women First HealthCare, Inc. cautions you that any forward-looking information is not a guarantee of future performance. Women First HealthCare Inc. disclaims any intent or obligation to update these forward-looking statements. Actual results could differ materially due to a number of factors, including (i) we may not maintain compliance with the new covenant levels established with respect to the senior secured notes; (ii) we have incurred significant losses since we were founded in November 1996, and if midlife women do not use, and their clinicians do not recommend, the products we offer, we will experience losses in the future; (iii) there is a limited market awareness of our Company and the products and services we offer; (iv) we may not be able to identify appropriate acquisition, licensing, or co-promotion candidates in the future or to take advantage of the opportunities we identify; (v) we and our products face significant competition; (vi) our products may not achieve or maintain market acceptance for a variety of reasons, including as a result of recent research published by the National Cancer Institute and the National Institutes of Health concerning estrogen replenishment therapy and combination estrogen/progestin hormonal replenishment therapy in healthy menopausal women, respectively; (vii) if we do not successfully manage any growth we experience, we may experience increased expenses without corresponding revenue increases; (viii) we are dependent on single sources of supply for all of the products we offer; (ix) reduced consumer confidence could adversely affect sales by our Consumer Business Division; (x) our third party suppliers and licensors may terminate their agreements with us earlier than we expect, and as a result we may be unable to continue to market and sell the related pharmaceutical products on an exclusive basis or at all; (xi) if we overestimate demand for our products, we may be required to write off inventories and/or increase our reserves in future periods, (xii) we have incurred significant debt obligations which will require us to make debt service payments in the future; and (xiii) additional factors set forth in the Company's Securities and Exchange Commission filings including its Annual Report on Form 10-K for the period ended Dec. 31, 2002 and its Form 10-Q for the period ended June 30, 2003.

Contact Information:

John Jason
Vice President - Marketing

Target Software, Inc.
1245 S. Cedar Crest Blvd.
Allentown PA 18103

Tel: 610-289-3333 x2184
Fax: 610-820-9394
Email: John Jason